Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2015-10-30

Clinical Trial Update: A Study Comparing Vemurafenib Versus Vemurafenib Plus Cobimetinib in Participants With Metastatic Melanoma [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing vemurafenib alone versus vemurafenib with cobimetinib in metastatic melanoma has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Cobimetinib (cobimetinib)
  • Vemurafenib (vemurafenib)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Malignant Melanoma | Phase 3 | Status: COMPLETED | Results posted: 2015-10-30